PT4

• UNSPSC Description:

  PT4 is a therapeutic agent against Cutaneous leishmaniasis (CL). PT4 is effective against both species of Leishmania, with IC50s of 125.18 and 233.18 μM for L. amazonensis and L. braziliensis, respectively. PT4 decreases of mitochondrial membrane potential and increases production of reactive oxygen species, which leads to parasite death. PT4 has a potent in vivo anti-inflammatory activity[1].

• Target Antigen:

  Parasite; Reactive Oxygen Species

• Type:

  Reference compound

• Related Pathways:

  Anti-infection;Immunology/Inflammation;Metabolic Enzyme/Protease;NF-κB

• Applications:

  COVID-19-immunoregulation

• Field of Research:

  Infection; Inflammation/Immunology

• Assay Protocol:

  https://www.medchemexpress.com/pt4.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C1N(CCN2N=NC(C3=CC=CC=C3)=C2)C(C4=C1C=CC=C4)=O

• Molecular Weight:

  318.33

• References & Citations:

  [1]Vanderlan Nogueira Holanda, et al. Antileishmanial activity of 4-phenyl-1-[2-(phthalimido-2-yl)ethyl]-1H-1,2,3-triazole (PT4) derivative on Leishmania amazonensis and Leishmania braziliensis: In silico ADMET, in vitro activity, docking and m

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  1280738-47-7